CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

Zalicus

CombinatoRx, Incorporated Files Registration Statement for Proposed Initial Public Offering

December 13, 2004

BOSTON, Dec. 13 /PRNewswire/ -- CombinatoRx, Incorporated announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of its common stock. All of the shares of common stock will be offered by the Company. SG Cowen & Co., LLC is acting as sole book-running manager, Pacific Growth Equities, LLC is acting as co-lead manager, and SunTrust Robinson Humphrey and A.G. Edwards are acting as co-managers for the proposed offering. The number of shares to be offered and the price range for the offering have not yet been determined. This offering will be made only by means of a prospectus. A preliminary prospectus for the offering may be obtained, when available, from SG Cowen & Co., LLC, Prospectus Department, 1221 Avenue of the Americas, New York, NY 10020.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor offers to buy be accepted prior to the time the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About CombinatoRx

CombinatoRx, Incorporated is a biopharmaceutical company focused on developing new medicines built from synergistic combinations of approved drugs, designed to attack disease on multiple fronts. CombinatoRx applies its proprietary combination drug discovery technology to identify new combination product candidates in a number of disease areas, including immuno-inflammatory disease, oncology and metabolic disease. By applying our proprietary screening technology, we have discovered and advanced into clinical trials a portfolio of seven product candidates targeting multiple diseases.

Forward-Looking Statement

This press release contains forward-looking statements concerning CombinatoRx's plan to issue common stock, its plans for its product candidates, and plans for other research and development programs. CombinatoRx may not be successful in issuing the common stock due to market conditions or otherwise and, if the offering is completed, may not use the net proceeds for some of the potential purposes described above.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding CombinatoRx, Incorporated's business which are not historical facts are "forward-looking statements" that involve risks and uncertainties. Forward-looking statements can be identified by, among other things, the use of forward looking language, such as "anticipate," "believe," "could," "estimate," "expect," "future," "intends," "may," "plans," "should," "seeks," "potential," "will," or the negative of those terms, or other variations of those terms of comparable language, or by discussions of strategy or intentions. A number of important factors could cause actual results to differ materially from those projected or suggested in the forward looking statements including, but not limited to, the ability of CombinatoRx to: (i) successfully consummate the initial public offering, (ii) discover product candidates, (iii) successfully conduct preclinical and clinical trials of product candidates, (iv) obtain regulatory approval of any product candidates, (v) obtain and enforce intellectual property rights and (vi) the effect of capital market conditions and additional financing requirements. These statements speak only as of the date of this press release and the Company assumes no obligation or responsibility to update or revise the statements. For a discussion of such risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see "Risk Factors" in CombinatoRx's Registration Statement filed with the Securities and Exchange Commission.

Contact:

Robert Forrester
Executive Vice President, Chief Financial Officer
Phone: 617-425-7000